TriSalus Life Sciences, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+59.8% +$5M
$13M
Cost of Revenue↑+44.9% +$546K
$2M
Gross Profit↑+62.4% +$4M
$11M
R&D↓-13.1% -$389K
$3M
D&A↓-34.7% -$67K
$126K
Operating Income↓-3.1% -$275K
$-9M
EBITDA↓-34.7% -$67K
$126K
Interest Expense↑+36.0% +$384K
$1M
Interest Income↑+210.5% +$120K
$177K
Other Income/Expense↓-106.9% -$8M
$-502K
Pretax Income↓-349.9% -$8M
$-11M
Tax Provision
$0
Net Income↓-350.6% -$8M
$-11M
Gross Margin↑+1.4pts
86.7%
Operating Margin↑+41.0pts
-77.9%
Net Margin↓-60.8pts
-93.5%
Effective Tax Rate↓-0.2pts
-0.0%
DTA Valuation Allowance
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-1.9pts
3.2%
Revenue YoY Variation↑+15.4pts
59.8%
Income YoY Variation↓-56.2pts
-3.1%
Revenue QoQ Variation↑+1.8pts
14.2%
Income QoQ Variation↓-16.0pts
-22.9%